Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice

BACKGROUND: Current therapies fail to cure over a third of osteosarcoma patients and around three quarters of those with metastatic disease. “Smac mimetics” (also known as “IAP antagonists”) are a new class of anti-cancer agents. Previous work revealed that cells from murine osteosarcomas were effic...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Cancer
Hlavní autoři: Shekhar, Tanmay M., Burvenich, Ingrid J. G., Harris, Michael A., Rigopoulos, Angela, Zanker, Damien, Spurling, Alex, Parker, Belinda S., Walkley, Carl R., Scott, Andrew M., Hawkins, Christine J.
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6744692/
https://ncbi.nlm.nih.gov/pubmed/31521127
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-6103-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky